The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Mechanism of dimer selectivity and binding cooperativity of BRAF inhibitors
Published version of a preprint
Abstract
Aberrant signaling of BRAF V600E is a major cancer driver. Current FDA-approved RAF inhibitors selectively inhibit the monomeric BRAF V600E and suffer from tumor resistance. Recently, dimer-selective and equipotent RAF inhibitors have been developed; however, the mechanism of dimer selectivity is poorly understood. Here, we report extensive molecular dynamics (MD) simulations of the monomeric and dimeric BRAF V600E in the apo form or in complex with one or two dimer-selective (PHI1) or equipotent (LY3009120) inhibitor(s). The simulations uncovered the unprecedented details of the remarkable allostery in BRAF V600E dimerization and inhibitor binding. Specifically, dimerization retrains and shifts the αC helix inward and increases the flexibility of the DFG motif; dimer compatibility is due to the promotion of the αC-in conformation, which is stabilized by a hydrogen bond formation between the inhibitor and the αC Glu501. A more stable hydrogen bond further restrains and shifts the αC helix inward, which incurs a larger entropic penalty that disfavors monomer binding. This mechanism led us to propose an empirical way based on the co-crystal structure to assess the dimer selectivity of a BRAF V600E inhibitor. Simulations also revealed that the positive cooperativity of PHI1 is due to its ability to preorganize the αC and DFG conformation in the opposite protomer, priming it for binding the second inhibitor. The atomically detailed view of the interplay between BRAF dimerization and inhibitor allostery as well as cooperativity has implications for understanding kinase signaling and contributes to the design of protomer selective RAF inhibitors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Recent experimental and computational investigations have provided additional structural and dynamic evidence for the role of positive cooperativity in the paradoxical activation of the BRAF homodimer [43].”
From Allosteric binding cooperativity in kinases signaling, signalopathies, and drug development (2025) · cites this paper as [43]
In the citing paper
“Other kinases demonstrate that nucleotide binding can either enhance or reduce the affinity for substrates (37–39) and can also contribute to dimerization (40, 41).”
From Local and distal changes in dynamics are caused by an L205R Cushing’s syndrome mutant in PRKACA (2025) · cites this paper as [41]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)
Poulikakos, P. I., Persaud, Y., Janakiraman, M., Kong, X., Ng, C., Moriceau, G., Shi, H., Atefi, M., Titz, B., Gabay, M. T., et al. (2011) · Nature · doi:10.1038/nature10662 · Cited by 1,454
Self-citationTargeting RAS–ERK signalling in cancer: promises and challenges
Samatar, A. A., & Poulikakos, P. I. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4281 · Cited by 1,163
Self-citationNew perspectives for targeting RAF kinase in human cancer
Karoulia, Z., Gavathiotis, E., & Poulikakos, P. I. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.79 · Cited by 404
Self-citationARAF mutations confer resistance to the RAF inhibitor belvarafenib in melanoma
Yen, I., Shanahan, F., Lee, J., Hong, Y. S., Shin, S. J., Moore, A. R., Sudhamsu, J., Chang, M. T., Bae, I., Dela Cruz, D., et al. (2021) · Nature · doi:10.1038/s41586-021-03515-1 · Cited by 138
Towards simple kinetic models of functional dynamics for a kinase subfamily
Sultan, M. M., Kiss, G., & Pande, V. S. (2018) · Nature Chemistry · doi:10.1038/s41557-018-0077-9 · Cited by 68
Research works printed but not linked: 40
- Adamopoulos, 2021, Exploiting allosteric properties of raf and mek inhibitors to target therapy-resistant tumors driven by oncogenic BRAF signaling, Cancer Discovery, 11, 1716, 10.1158/2159-8290.CD-20-1351 · DOI
- Brooks, 2009, CHARMM: The biomolecular simulation program, Journal of Computational Chemistry, 30, 1545, 10.1002/jcc.21287 · DOI · Paper page
- Case, 2020, AMBER 2020
- Clayton J, Shen J. 2024. RAF. Software Heritage. swh:1:rev:8f2e939ee7f4b42583b62cb09d6a0295ae327280. https://archive.softwareheritage.org/swh:1:dir:fc9557b9c32c386d652a37124cab072f9c9f16ce;origin=https://github.com/JanaShenLab/RAF;visit=swh:1:snp:bdd193c7b074e905ca876c3592a6c01c9b5aba54;anchor=swh:1:rev:8f2e939ee7f4b42583b62cb09d6a0295ae327280.
- Cook, 2021, Inhibition of RAF dimers: it takes two to tango, Biochemical Society Transactions, 49, 237, 10.1042/BST20200485 · DOI
- Cotto-Rios, 2020, Inhibitors of BRAF dimers using an allosteric site, Nature Communications, 11, 10.1038/s41467-020-18123-2 · DOI
- Darden, 1993, Particle mesh Ewald: An N ⋅log(N) method for Ewald sums in large systems, The Journal of Chemical Physics, 98, 10089, 10.1063/1.464397 · DOI · Paper page
- Feller, 1995, Constant pressure molecular dynamics simulation: the Langevin piston method, The Journal of Chemical Physics, 103, 4613, 10.1063/1.470648 · DOI · Paper page
- Grasso, 2016, Chemically linked vemurafenib inhibitors promote an inactive BRAFV600E conformation, ACS Chemical Biology, 11, 2876, 10.1021/acschembio.6b00529 · DOI
- Harris, 2022, GPU-accelerated all-atom particle-mesh ewald continuous constant pH molecular dynamics in amber, Journal of Chemical Theory and Computation, 18, 7510, 10.1021/acs.jctc.2c00586 · DOI
- Hatzivassiliou, 2010, RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth, Nature, 464, 431, 10.1038/nature08833 · DOI · Paper page
- Henderson, 2020, Assessment of proton-coupled conformational dynamics of SARS and MERS coronavirus papain-like proteases: Implication for designing broad-spectrum antiviral inhibitors, The Journal of Chemical Physics, 153, 10.1063/5.0020458 · DOI
- Henderson, 2022, A guide to the continuous constant ph molecular dynamics methods in amber and CHARMM, Living Journal of Computational Molecular Science, 4, 10.33011/livecoms.4.1.1563 · DOI
- Hopkins, 2015, Long-time-step molecular dynamics through hydrogen mass repartitioning, Journal of Chemical Theory and Computation, 11, 1864, 10.1021/ct5010406 · DOI · Paper page
- Jorgensen, 1983, Comparison of simple potential functions for simulating liquid water, The Journal of Chemical Physics, 79, 926, 10.1063/1.445869 · DOI · Paper page
- Kanev, 2021, KLIFS: an overhaul after the first 5 years of supporting kinase research, Nucleic Acids Research, 49, D562, 10.1093/nar/gkaa895 · DOI · Paper page
- Karoulia, 2016, An integrated model of RAF inhibitor action predicts inhibitor activity against oncogenic BRAF signaling, Cancer Cell, 30, 485, 10.1016/j.ccell.2016.06.024 · DOI · Paper page
- King, 2006, Demonstration of a genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885, Cancer Research, 66, 11100, 10.1158/0008-5472.CAN-06-2554 · DOI · Paper page
- Kooistra, 2016, KLIFS: A structural kinase-ligand interaction database, Nucleic Acids Research, 44, D365, 10.1093/nar/gkv1082 · DOI · Paper page
- Lavoie, 2013, Inhibitors that stabilize a closed RAF kinase domain conformation induce dimerization, Nature Chemical Biology, 9, 428, 10.1038/nchembio.1257 · DOI · Paper page
- Lavoie, 2020, ERK signalling: A master regulator of cell behaviour, life and fate, Nature Reviews Molecular Cell Biology, 21, 607, 10.1038/s41580-020-0255-7 · DOI · Paper page
- Liao, 2007, Molecular recognition of protein kinase binding pockets for design of potent and selective kinase inhibitors, Journal of Medicinal Chemistry, 50, 409, 10.1021/jm0608107 · DOI · Paper page
- Maier, 2015, ff14SB: improving the accuracy of protein side chain and backbone parameters from ff99SB, Journal of Chemical Theory and Computation, 11, 3696, 10.1021/acs.jctc.5b00255 · DOI · Paper page
- Maloney, 2021, The mechanism of activation of monomeric B-Raf V600E, Computational and Structural Biotechnology Journal, 19, 3349, 10.1016/j.csbj.2021.06.007 · DOI
- Möbitz, 2015, The ABC of protein kinase conformations, Biochimica et Biophysica Acta, 1854, 1555, 10.1016/j.bbapap.2015.03.009 · DOI
- Monaco, 2021, LXH254, a potent and selective ARAF-Sparing inhibitor of BRAF and CRAF for the treatment of MAPK-driven tumors, Clinical Cancer Research, 27, 2061, 10.1158/1078-0432.CCR-20-2563 · DOI
- Peng, 2015, Inhibition of RAF isoforms and active dimers by LY3009120 leads to anti-tumor activities in RAS or BRAF mutant cancers, Cancer Cell, 28, 384, 10.1016/j.ccell.2015.08.002 · DOI · Paper page
- Poulikakos, 2010, RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF, Nature, 464, 427, 10.1038/nature08902 · DOI · Paper page
- Rajakulendran, 2009, A dimerization-dependent mechanism drives RAF catalytic activation, Nature, 461, 542, 10.1038/nature08314 · DOI · Paper page
- Rasmussen, 2023, Allosteric coupling asymmetry mediates paradoxical activation of BRAF by type ii inhibitors, 10.1101/2023.04.18.536450 · DOI
- Roe, 2013, PTRAJ and CPPTRAJ: software for processing and analysis of molecular dynamics trajectory data, Journal of Chemical Theory and Computation, 9, 3084, 10.1021/ct400341p · DOI · Paper page
- Schrödinger LLC. 2015. The pymol molecular graphics system. pYmol. 8. https://pymol.org/.
- Thevakumaran, 2015, Crystal structure of a BRAF kinase domain monomer explains basis for allosteric regulation, Nature Structural & Molecular Biology, 22, 37, 10.1038/nsmb.2924 · DOI · Paper page
- Tkacik, 2023, Structure and RAF family kinase isoform selectivity of type II RAF inhibitors tovorafenib and naporafenib, The Journal of Biological Chemistry, 299, 10.1016/j.jbc.2023.104634 · DOI
- Tsai, 2019, How electrostatic coupling enables conformational plasticity in a tyrosine kinase, Journal of the American Chemical Society, 141, 15092, 10.1021/jacs.9b06064 · DOI
- Tse, 2016, Exploring molecular mechanisms of paradoxical activation in the BRAF kinase dimers: atomistic simulations of conformational dynamics and modeling of allosteric communication networks and signaling pathways, PLOS ONE, 11, 10.1371/journal.pone.0166583 · DOI
- Wallace, 2011, Continuous constant pH molecular dynamics in explicit solvent with pH-based replica exchange, Journal of Chemical Theory and Computation, 7, 2617, 10.1021/ct200146j · DOI · Paper page
- Wang, 2004, Development and testing of a general amber force field, Journal of Computational Chemistry, 25, 1157, 10.1002/jcc.20035 · DOI · Paper page
- Yao, 2018, Elucidating allosteric communications in proteins with difference contact network analysis, Journal of Chemical Information and Modeling, 58, 1325, 10.1021/acs.jcim.8b00250 · DOI
- Zhang, 2021, The mechanism of Raf activation through dimerization, Chemical Science, 12, 15609, 10.1039/D1SC03444H · DOI
Cited by
Allosteric binding cooperativity in kinases signaling, signalopathies, and drug development
Olivieri, C., Wu, J., Taylor, S. S., & Veglia, G. (2025) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2025.103169 · Cited by 1
Local and distal changes in dynamics are caused by an L205R Cushing’s syndrome mutant in PRKACA
Kalle, A., Wu, J., Tawfeeq, C., Kornev, A. P., Veglia, G., Maillard, R., Taylor, S. S., & Jonniya, N. A. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2502898122 · Cited by 1
Metadata
- Authors
- Clayton, J., Romany, A., Matenoglou, E., Gavathiotis, E., Poulikakos, P. I., & Shen, J.
- Affiliations
- Department of Pharmaceutical Sciences, University of Maryland School of Pharmacy
- Department of Biochemistry, Department of Medicine, Department of Oncology, Montefiore Einstein Comprehensive Cancer Center, Albert Einstein College of Medicine
- Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai
- Venue
- eLife
- Publisher
- eLife Sciences Publications, Ltd
- Published
- 2025-02-13
- Volume
- 13
- ISSN
- 2050-084X
- Cited by
- 7
- References
- 5
- Language
- en
- Licence
- creativecommons.org/licenses/by/4.0/ (vor)
- creativecommons.org/licenses/by/4.0/ (am)
- creativecommons.org/licenses/by/4.0/ (tdm)
- Funders
- National Institutes of Health (R01CA256557, R01CA238229)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.